68 research outputs found
The European Map of Job Flows
The European Map of Job Flows (EMJF) is a term used to denote a dataset of meso- and macro-level variables describing different aspect of labour mobility within national labour markets in Europe. In this paper, EMJF is centred on the notion of job “flows”, namely the changes in the level of employment at different breakdowns and levels of aggregation. EMJF is very rich in information content due to the wide variety of possible breakdown of the data and in this sense it is a “map” mostly in the virtual sense, namely, that it is not possible to visualise in the form of geographic maps all the wealth of available information. In terms of its value as a research product and tool, EMJF is mostly an intermediate product in the sense that it is a convenient means to organise the relevant information, which could subsequently be used for different analytical and research purposes. It provides both for cross-sections/snapshots of job flows at different point in time but also it allows their assessment and analysis over longer periods of time. In this sense, EMJF can be widely used for various types of labour-market analysis and research. EMJF’s visual components can also be a convenient tool for policy makers dealing with labour market policies at different level (regional, national or supra-national) in the decision-making process. Here we present a Compilation of a EMJF on the basis of firm-level data In this sense the job flows are built up on the basis of firm-level data for individual countries, following a common methodology. We adopt an approach of establishing such a EMJF on the basis of the AMADEUS dataset developed by the consultancy Bureau van Dijk. The dataset in its most extended version contains balance sheet data and ownership data for almost 14 million firms from 43 different European countries (September 2009 update). For many EU countries the dataset has in principle access to the entire universe of firms which have to report a balance sheet. In terms of countries, the geographic coverage of AMADEUS encompasses information for all the 27 members of the European Union (albeit with different qualities in terms of national coverage) as well as other 16 European countries that complete the geographical and political definition of the continent. Another interesting feature of the database is given by the detailed definition of a firm's location, with data available on the region (NUTS2) and the city in which the firm operates. This project deliverable presents the main results from the final stage of MICRO-DYN work on the EMJF. It discusses the approach to building the EMJF on the basis of AMADEUS data and illustrates the analytical potential of the EMJF as a research tool with a range of Europe-wide analytical exercises. Probably the most important outcome of this research effort is the demonstrated capability to perform meta-analysis at the European level of important labour market characteristics on the basis of firm-level data.job flows, europe, labor market, microdata
The European Map of Job Flows
The European Map of Job Flows (EMJF) is a term used to denote a dataset of meso- and macro-level variables describing different aspect of labour mobility within national labour markets in Europe. In this paper, EMJF is centred on the notion of job “flows”, namely the changes in the level of employment at different breakdowns and
levels of aggregation. EMJF is very rich in information content due to the wide variety of possible breakdown of the data and in this sense it is a “map” mostly in the virtual sense, namely, that it is not possible to visualise in the form of geographic maps all the wealth of available information. In terms of its value as a research product and tool, EMJF is mostly an intermediate product in the sense that it is a convenient means to organise the relevant information, which could subsequently be used for different analytical and research purposes. It provides both for cross-sections/snapshots of job flows at different point in time but also it allows their assessment and analysis over longer periods of time. In this sense, EMJF can be widely used for various types of labour-market analysis and research. EMJF’s visual components can also
be a convenient tool for policy makers dealing with labour market policies at different level (regional, national or supra-national) in the decision-making process. Here we present a Compilation of a EMJF on the basis of firm-level data In this sense the job flows are built up on the
basis of firm-level data for individual countries, following a common methodology. We adopt an approach of establishing such a EMJF on the basis of the AMADEUS dataset developed by the consultancy Bureau van Dijk. The dataset in its most extended version contains balance sheet data and ownership data for almost 14 million firms from 43 different European countries (September 2009 update). For many EU countries the dataset has in principle access to the entire universe of firms which have to report a
balance sheet. In terms of countries, the geographic coverage of AMADEUS encompasses information for all the 27 members of the European Union (albeit with different qualities in terms of national coverage) as well as other 16 European countries that complete the geographical and political definition of the continent. Another interesting feature of the database is given by the detailed definition of a firm's location, with data available on the region (NUTS2) and the city in which the firm operates. This project deliverable presents the main results from the final stage of MICRO-DYN work on the EMJF. It discusses the approach to building the EMJF on the basis of AMADEUS data and illustrates the analytical potential of the EMJF as a research tool with a range of Europe-wide analytical exercises. Probably the most important outcome of this
research effort is the demonstrated capability to perform meta-analysis at the European level of important labour market characteristics on the basis of firm-level data
The European Map of Job Flows
The European Map of Job Flows (EMJF) is a term used to denote a dataset of meso- and macro-level variables describing different aspect of labour mobility within national labour markets in Europe. In this paper, EMJF is centred on the notion of job “flows”, namely the changes in the level of employment at different breakdowns and
levels of aggregation. EMJF is very rich in information content due to the wide variety of possible breakdown of the data and in this sense it is a “map” mostly in the virtual sense, namely, that it is not possible to visualise in the form of geographic maps all the wealth of available information. In terms of its value as a research product and tool, EMJF is mostly an intermediate product in the sense that it is a convenient means to organise the relevant information, which could subsequently be used for different analytical and research purposes. It provides both for cross-sections/snapshots of job flows at different point in time but also it allows their assessment and analysis over longer periods of time. In this sense, EMJF can be widely used for various types of labour-market analysis and research. EMJF’s visual components can also
be a convenient tool for policy makers dealing with labour market policies at different level (regional, national or supra-national) in the decision-making process. Here we present a Compilation of a EMJF on the basis of firm-level data In this sense the job flows are built up on the
basis of firm-level data for individual countries, following a common methodology. We adopt an approach of establishing such a EMJF on the basis of the AMADEUS dataset developed by the consultancy Bureau van Dijk. The dataset in its most extended version contains balance sheet data and ownership data for almost 14 million firms from 43 different European countries (September 2009 update). For many EU countries the dataset has in principle access to the entire universe of firms which have to report a
balance sheet. In terms of countries, the geographic coverage of AMADEUS encompasses information for all the 27 members of the European Union (albeit with different qualities in terms of national coverage) as well as other 16 European countries that complete the geographical and political definition of the continent. Another interesting feature of the database is given by the detailed definition of a firm's location, with data available on the region (NUTS2) and the city in which the firm operates. This project deliverable presents the main results from the final stage of MICRO-DYN work on the EMJF. It discusses the approach to building the EMJF on the basis of AMADEUS data and illustrates the analytical potential of the EMJF as a research tool with a range of Europe-wide analytical exercises. Probably the most important outcome of this
research effort is the demonstrated capability to perform meta-analysis at the European level of important labour market characteristics on the basis of firm-level data
HCC recurrence in HCV-infected patients after liver transplantation: SiLVER Study reveals benefits of sirolimus in combination with CNIs - a post-hoc analysis
Factors affecting outcomes in liver transplant (LTx) recipients with hepatocellular carcinoma (HCC) and hepatitis C viral (HCV) infection include the choice of immunosuppression. Here, we analyzed the HCV+ subgroup of patients from the randomized controlled, international SiLVER Study. We performed a post hoc analysis of 166 HCV+ SiLVER Study patients regarding HCC outcome after LTx. Control patients (group A: n = 88) received mTOR inhibitor (mTORi)-free, calcineurin inhibitor (CNI)-based versus sirolimus-based immunosuppression (group B: n = 78). We found no significant difference regarding HCV-RNA titers between group A and B. Since no effect in group B could be due to variable sirolimus dosing, we split group B into patients receiving sirolimus-based immunosuppression + CNIs for >50% (B1; n = 44) or <50% (B2; n = 34) of the time. While there remained no difference in HCV-RNA titer between groups, HCC recurrence-free survival in group B1 (81.8%) was markedly better versus both group A (62.7%; P = 0.0136) and group B2 (64.7%; P = 0.0326); Interestingly, further subgroup analysis revealed an increase (P = 0.0012) in liver enzyme values in group B2. Taken together, in HCV-infected patients with HCC and LTx, mTORi immunosuppression + CNIs yields excellent outcomes. Unexpectedly, higher levels of liver inflammation and poorer outcomes occur with mTORi monotherapy in the HCV+ subgroup
Study of Li-10 via the Li-9(H-2, p) reaction at REX-ISOLDE
The Click to view the MathML source reaction has been investigated at 2.36 MeV/u at the REX-ISOLDE facility. In this Letter we focus on the Click to view the MathML source channel which potentially holds spectroscopic information on the unbound nucleus 10Li. The experimental excitation energy spectrum and angular distribution are compared with CCBA calculations. These calculations clearly support the existence of a low-lying (s) virtual state, with a (negative) scattering length of the order asnot, vert, similar1324 fm and a p1/2 resonance with an energy of Ersimilar, equals0.38 MeV and a width of Γsimilar, equals0.2 MeV
Evaluation of the efficacy and reproducibility of cholangiopancreatography by magnetic resonance for detecting biliary complications following orthotopic liver transplantation
A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma
<p>Abstract</p> <p>Background</p> <p>The potential anti-cancer effects of mammalian target of rapamycin (mTOR) inhibitors are being intensively studied. To date, however, few randomised clinical trials (RCT) have been performed to demonstrate anti-neoplastic effects in the pure oncology setting, and at present, no oncology endpoint-directed RCT has been reported in the high-malignancy risk population of immunosuppressed transplant recipients. Interestingly, since mTOR inhibitors have both immunosuppressive and anti-cancer effects, they have the potential to simultaneously protect against immunologic graft loss and tumour development. Therefore, we designed a prospective RCT to determine if the mTOR inhibitor sirolimus can improve hepatocellular carcinoma (HCC)-free patient survival in liver transplant (LT) recipients with a pre-transplant diagnosis of HCC.</p> <p>Methods/Design</p> <p>The study is an open-labelled, randomised, RCT comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing LT for HCC. Patients with a histologically confirmed HCC diagnosis are randomised into 2 groups within 4-6 weeks after LT; one arm is maintained on a centre-specific mTOR-inhibitor-free immunosuppressive protocol and the second arm is maintained on a centre-specific mTOR-inhibitor-free immunosuppressive protocol for the first 4-6 weeks, at which time sirolimus is initiated. A 2<sup>1/2</sup> -year recruitment phase is planned with a 5-year follow-up, testing HCC-free survival as the primary endpoint. Our hypothesis is that sirolimus use in the second arm of the study will improve HCC-free survival. The study is a non-commercial investigator-initiated trial (IIT) sponsored by the University Hospital Regensburg and is endorsed by the European Liver and Intestine Transplant Association; 13 countries within Europe, Canada and Australia are participating.</p> <p>Discussion</p> <p>If our hypothesis is correct that mTOR inhibition can reduce HCC tumour growth while simultaneously providing immunosuppression to protect the liver allograft from rejection, patients should experience less post-transplant problems with HCC recurrence, and therefore could expect a longer and better quality of life. A positive outcome will likely change the standard of posttransplant immunosuppressive care for LT patients with HCC.</p> <p>Trial Register</p> <p>Trial registered at <url>http://www.clinicaltrials.gov</url>: NCT00355862</p> <p>(EudraCT Number: 2005-005362-36)</p
A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma
Peer reviewe
- …